Pharmacology · Antifungal Agents

Clinical Syndromes — Candidiasis, Aspergillosis, Cryptococcosis, Mucormycosis & Endemic Mycoses

Drug of choice by syndrome, critical distinctions, and geographic clues

Echinocandins are first-line for all candidemia — not fluconazole; echinocandin therapy should begin immediately, with de-escalation to fluconazole permissible after 5–7 days only when the patient is stable, blood cultures are negative, and the species is confirmed susceptible.
Voriconazole has zero activity against the Mucorales — a patient who develops breakthrough mucormycosis while on voriconazole prophylaxis must be switched immediately to liposomal amphotericin B; this distinction cannot be missed at the bedside because the clinical presentations of aspergillosis and mucormycosis can be identical on CT.
Cryptococcal meningitis: antiretroviral therapy must be deferred 2–4 weeks after starting antifungal induction — early ART (within 2 weeks) dramatically increases mortality through IRIS; the 2022 WHO guideline supports a 1-week induction regimen (liposomal AmB + flucytosine + fluconazole).
Coccidioidal meningitis requires lifelong fluconazole suppression — it cannot be cured and will relapse without indefinite maintenance therapy; this is the only endemic mycosis for which lifelong suppression is standard regardless of immune status.
The severe/life-threatening rule applies across all invasive mycoses except aspergillosis: liposomal amphotericin B induction, then azole step-down. For aspergillosis, voriconazole or isavuconazole is first-line from the outset — amphotericin B is an alternative, not the preferred agent.

Abbreviations: L-AmB = liposomal amphotericin B · TDM = therapeutic drug monitoring · ART = antiretroviral therapy · IRIS = immune reconstitution inflammatory syndrome · DKA = diabetic ketoacidosis · ICP = intracranial pressure · LP = lumbar puncture

Drug of Choice by Syndrome

Syndrome	First-Line	Alternative	Key Rules
Candidemia	Echinocandin (any)	Fluconazole (stable, low-risk only)	Remove all intravascular catheters; 14 days from last negative blood culture; de-escalate to fluconazole only when stable + susceptible species confirmed
Invasive Aspergillosis	Voriconazole or isavuconazole	L-AmB	TDM mandatory for voriconazole (trough 1–5.5 mg/L); test isolates for azole resistance; minimum 6–12 weeks; combination (vori + anidulafungin) may improve outcomes in severe disease
Cryptococcal Meningitis — Induction	L-AmB + flucytosine + fluconazole × 1 week (WHO 2022)	AmB deoxycholate + flucytosine × 1–2 weeks	Defer ART 2–4 weeks (IRIS risk); manage ICP with serial LP — target opening pressure <200 mm H₂O; daily LP may be required initially
Cryptococcal Meningitis — Consolidation	Fluconazole 400 mg daily × 8 weeks	—	Followed by maintenance: fluconazole 200 mg daily until CD4 >200 cells/μL on ART × 6 months; never stop maintenance prematurely
Mucormycosis	L-AmB 5 mg/kg/day + surgical debridement	Posaconazole or isavuconazole (step-down when stable)	Surgery is mandatory — cannot omit; voriconazole has NO activity; reverse predisposing factors (DKA, reduce steroids, treat neutropenia); delay is fatal
Histoplasmosis (mild-moderate)	Itraconazole (preferred)	Fluconazole (inferior — reserve for intolerance)	Severe/disseminated: L-AmB induction × 1–2 weeks then itraconazole × 12 months; urine antigen most sensitive for disseminated disease
Coccidioidomycosis	Fluconazole (including CNS)	Itraconazole (bone/joint preferred)	Meningitis: lifelong fluconazole suppression required — not curable; cannot discontinue; severe/disseminated non-CNS: L-AmB induction
Blastomycosis (mild-moderate)	Itraconazole × 6–12 months	—	Severe/CNS: L-AmB induction × 1–2 weeks then itraconazole × 12 months; obtain itraconazole TDM; blastomycosis disseminates even in immunocompetent hosts

High-Yield Clinical Distinctions

Aspergillosis vs. Mucormycosis

Critical Bedside Distinction

Both present as invasive mold infection in immunocompromised host — CT findings may be identical (nodules, halo sign, cavitation)
Aspergillosis: voriconazole or isavuconazole first-line — highly effective
Mucormycosis: voriconazole has NO activity — must use L-AmB; treating mucormycosis with voriconazole is equivalent to no treatment
Mucormycosis clinical clues: palatal/nasal eschar, periorbital swelling, black necrotic tissue, uncontrolled DKA, recent high-dose steroid or bone marrow transplant
Breakthrough mucormycosis on voriconazole prophylaxis → switch immediately to L-AmB and consult surgical team for debridement

Cryptococcal Meningitis

ART Timing and ICP Management

Defer ART 2–4 weeks after starting antifungals — early ART (within 2 weeks) increases mortality via IRIS (immune reconstitution to cryptococcal antigens)
Intracranial pressure management is a primary treatment target — elevated ICP (opening pressure >200 mm H₂O) must be reduced by serial lumbar puncture; acetazolamide and steroids are not effective for this indication
Daily LP may be required in the first week until ICP controlled; therapeutic LP removes 20–30 mL CSF and monitors opening pressure
Three phases: induction (AmB + 5-FC ± fluconazole, 1–2 weeks) → consolidation (fluconazole 400 mg × 8 weeks) → maintenance (fluconazole 200 mg until CD4 recovery)

Endemic Mycoses — Host and Geographic Clues

Histoplasmosis

Ohio and Mississippi River Valleys

Soil enriched with bird or bat droppings (Histoplasma capsulatum)
Fever, hepatosplenomegaly, pancytopenia in HIV patient — classic disseminated presentation
Urine antigen: most sensitive test for disseminated histoplasmosis (sensitivity ~90%)
Drug of choice: itraconazole (mild-moderate); L-AmB induction for severe/disseminated
Duration: 12 months for disseminated disease; indefinite in uncontrolled AIDS

Coccidioidomycosis

Desert Southwest — Valley Fever

Desert Southwest US, northern Mexico, parts of Central/South America (Coccidioides immitis/posadasii)
Erythema nodosum, erythema multiforme — immune-mediated clues in primary pulmonary infection
Meningitis: lifelong fluconazole 400–800 mg daily — cannot be cured; relapse fatal without continuous suppression
Bone/joint disease: itraconazole preferred; responds more slowly than pulmonary disease
Pregnancy increases dissemination risk significantly — treat aggressively

Blastomycosis

Ohio / Mississippi Valleys and Great Lakes

Ohio and Mississippi river valleys, Great Lakes region, Canada (Blastomyces dermatitidis)
Verrucous or ulcerative skin lesions — dissemination clue; also bone, genitourinary, CNS
Unique among endemic mycoses: disseminates even in immunocompetent hosts — do not dismiss without full evaluation
Drug of choice: itraconazole × 6–12 months (obtain TDM); L-AmB induction for severe or CNS disease
CNS disease: L-AmB × 4–6 weeks then itraconazole or voriconazole × 12 months

Chapter 37 Complete — Antifungal Agents: The Organizing Framework

Antifungal therapy follows a severity-based hierarchy. Superficial and mucosal disease: topical agents or narrow-spectrum oral azoles (fluconazole, itraconazole, terbinafine). Mild to moderate invasive disease in most endemic mycoses: itraconazole or fluconazole orally. Severe or life-threatening invasive disease — except aspergillosis: liposomal amphotericin B induction followed by azole step-down once the patient is stable. Invasive aspergillosis is the critical exception — voriconazole or isavuconazole is first-line from the outset; amphotericin B is the alternative, not the preferred agent. Mucormycosis is the second exception — voriconazole is contraindicated, and amphotericin B plus surgery is always required.

The same six mechanisms underpin every clinical decision: (1) polyenes bind ergosterol directly — broadest fungicidal spectrum, highest toxicity; (2) azoles inhibit ergosterol synthesis — fungistatic against most organisms, potent CYP inhibitors, species- and severity-dependent selection; (3) echinocandins inhibit glucan synthase — fungicidal against Candida, first-line for candidemia, no oral formulation; (4) flucytosine disrupts fungal nucleic acid synthesis — used only in combination for cryptococcal meningitis; (5) allylamines inhibit squalene epoxidase — fungicidal, confined to dermatophytes; (6) griseofulvin disrupts microtubules — fungistatic, confined to dermatophytes and largely superseded by terbinafine. Resistance in fungi is emerging across all major antifungal classes; susceptibility testing before definitive therapy is no longer optional.

Suggested References

Author / Source	Title	Publication
Katzung BG, ed.	Basic and Clinical Pharmacology, 15th ed. — Chapter 48: Antifungal Agents	McGraw-Hill, 2021
Brunton LL, Knollmann BC, eds.	Goodman & Gilman's The Pharmacological Basis of Therapeutics, 14th ed. — Chapter 57: Antifungal Agents	McGraw-Hill, 2023
Pappas PG, Kauffman CA, Andes DR, et al.	Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America	Clin Infect Dis. 2016;62(4):e1–e50
Kullberg BJ, Arendrup MC	Invasive fungal disease in the patient with cancer	N Engl J Med. 2015;373(15):1445–1456
Patterson TF, Thompson GR, Denning DW, et al.	Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America	Clin Infect Dis. 2016;63(4):e1–e60
Herbrecht R, Denning DW, Patterson TF, et al.	Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis	N Engl J Med. 2002;347(6):408–415
Perfect JR, Dismukes WE, Dromer F, et al.	Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America	Clin Infect Dis. 2010;50(3):291–322
World Health Organization	Guidelines for Diagnosing, Preventing and Managing Cryptococcal Disease Among Adults, Adolescents and Children Living with HIV	Geneva: WHO; 2022
Cornely OA, Alastruey-Izquierdo A, Arenz D, et al.	Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium	Lancet Infect Dis. 2019;19(12):e405–e421
Marr KA, Schlamm HT, Herbrecht R, et al.	Combination antifungal therapy for invasive aspergillosis: a randomized trial	Ann Intern Med. 2015;162(2):81–89
Wheat LJ, Freifeld AG, Kleiman MB, et al.	Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America	Clin Infect Dis. 2007;45(7):807–825
Galgiani JN, Ampel NM, Blair JE, et al.	2016 Infectious Diseases Society of America (IDSA) clinical practice guideline for the treatment of coccidioidomycosis	Clin Infect Dis. 2016;63(6):e112–e146